Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright

Repligen (NASDAQ:RGEN)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $180.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 13.21% from the stock’s previous close.

Several other equities research analysts have also weighed in on RGEN. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $158.99 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The firm has a market capitalization of $8.91 billion, a PE ratio of -311.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The stock’s 50-day simple moving average is $155.22 and its 200-day simple moving average is $148.68.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, equities research analysts forecast that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG acquired a new position in Repligen during the fourth quarter worth $29,000. Blue Trust Inc. grew its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. Finally, Resources Management Corp CT ADV acquired a new position in Repligen during the third quarter worth $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.